Influential opinions and insights on companies
Our equity analysts ask the right questions, dig deeper for answers and find details others miss. Our research division covers key Canadian healthcare companies to understand how they operate, recognize their relative strengths and weaknesses, and determine the impact of clinical and commercial developments and competitive events.
Specialized equity research that gets attention
Our analysts make influential buy, sell and hold recommendations in healthcare and biotechnology, gather industry knowledge, and provide insightful market intelligence to help guide our investor clients.
Charting what’s new in biotech: Bloom Burton’s Top Ideas; Healthcare Sector Review/Preview
Our Top Ideas; Healthcare Sector Review/Preview report, published annually, is essential reading for institutional investors to track historical sector performance and glean insight for the upcoming year, including milestones that could impact share performance.
Distribution of healthcare research
Bloom Burton’s research products are disseminated simultaneously to all our customers who are authorised to receive them. Request to be added to Bloom Burton’s equity research distribution list. Email Brian Bloom at firstname.lastname@example.org
Aralez Pharmaceuticals Canada Inc. (TSX: ARZ, NASDAQ:ARLZ)
Arbutus Biopharma Corporation (NASDAQ:ABUS)
Aurinia Pharmaceuticals Inc. (TSX:AUP, NASDAQ:AUPH)
BELLUS Health Inc. (TSX:BLU)
BioSyent Inc. (TSXV:RX)
Cardiome Pharma Corporation (TSX:COM, NASDAQ:CRME)
Cipher Pharmaceuticals Inc. (TSX:CPH)
Concordia Healthcare Corporation (TSX:CXR)
CRH Medical Corporation (TSX:CRH, NYSE-MKT:CRHM)
ESSA Pharma (TSX:EPI, NASDAQ:EPIX)
Knight Therapeutics Inc. (TSX:GUD)
Novelion Therapeutics (NASDAQ: NVLN)
Nuvo Pharmaceuticals (TSX:NRI)
ProMetic Life Sciences (TSX:PLI)
Trillium Therapeutics Inc. (TSX:TR, NASDAQ:TRIL)
Xenon Pharmaceuticals (NASDAQ:XENE)